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Abstract
Background: The voltage-gated sodium channel b2 subunit (Navb2) is a physiological substrate of BACE1 (b-site
APP cleaving enzyme) and g-secretase, two proteolytic enzymes central to Alzheimer’s disease pathogenesis.
Previously, we have found that the processing of Navb2 by BACE1 and g-secretase regulates sodium channel
metabolism in neuronal cells. In the current study we identified the BACE1 cleavage sites in human Navb2.
Results: We found a major (147-148 L↓M, where ↓ indicates the cleavage site) and a minor (144145 L↓Q) BACE1
cleavage site in the extracellular domain of human Navb2 using a cell-free BACE1 cleavage assay followed by mass
spectrometry. Next, we introduced two different double mutations into the identified major BACE1 cleavage site in
human Navb2: 147LM/VI and 147LM/AA. Both mutations dramatically decreased the cleavage of human Navb2b y
endogenous BACE1 in cell-free BACE1 cleavage assays. Neither of the two mutations affected subcellular
localization of Navb2 as confirmed by confocal fluorescence microscopy and subcellular fractionation of
cholesterol-rich domains. Finally, wildtype and mutated Navb2 were expressed along BACE1 in B104 rat
neuroblastoma cells. In spite of a-secretase still actively cleaving the mutant proteins, Navb2 cleavage products
decreased by ~50% in cells expressing Navb2 (147LM/VI) and ~75% in cells expressing Navb2 (147LM/AA) as
compared to cells expressing wildtype Navb2.
Conclusion: We identified a major (147-148 L↓M) and a minor (144-145 L↓Q) BACE1 cleavage site in human
Navb2. Our in vitro and cell-based results clearly show that the 147-148 L↓M is the major BACE1 cleavage site in
human Navb2. These findings expand our understanding of the role of BACE1 in voltage-gated sodium channel
metabolism.
Background
BACE1/b-secretase is an aspartic protease highly
expressed in neuronal cells [1,2]. Together with preseni-
lin/g-secretase, BACE1 cleaves the amyloid precursor
protein (APP) to generate amyloid b peptides (Ab). Ab
accumulates in the brains of Alzheimer’s disease patients
where it promotes disease pathology [3,4]. In addition to
contributing to Ab generation, BACE1 regulates emo-
tional memory, synaptic function and myelination in
m o u s eb r a i n sp o s s i b l yb yc l e a v i n gm u l t i p l en e u r o n a l
substrates [5-7]. More than 60 BACE1 substrates have
recently been identified via quantitative proteomics [8].
However, only a few substrates have been investigated
and confirmed in vivo [6,9-12]. Cleavage of substrate
proteins may contribute to the important function of
BACE1 in development and maintenance of the nervous
system but the detailed molecular mechanism is not
known.
Voltage-gated sodium channels (Nav) are composed of
central a subunits and one or two accessory b subunits
[13]. The pore forming a subunits regulate sodium ion
transport in neuronal membranes and are therefore
essential for neuronal membrane excitability [13]. The
b subunits are type I transmembrane proteins with
extracellular immunoglobulin and short intracellular
C-terminal domains. Interaction of b subunits with
a subunits regulates Nav assembly and activity [13-15].
In particular, the b2 subunit (Navb2) regulates cell-sur-
face expression and inactivation kinetics of Nav chan-
nels in neurons [16,17]. In addition, b subunits
modulate cell adhesion and neurite outgrowth [18-20].
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ADAM10, BACE1, and g-secretase cleave Navb2 in neu-
ronal cells and mouse brains [11,12]. In a follow-up
study, we showed that elevated BACE1 activity increased
release of Navb2-ICD (intracellular domain) through
cleavage of Navb2 resulting in elevated protein and
mRNA levels of Nav1.1 a subunits in neuroblastoma
cells [21,22]. Furthermore, processing of endogenous
Navb2 and Nav1.1 protein levels were elevated in
BACE1-transgenic mouse brains and eventually resulted
in altered sodium current densities in hippocampal neu-
rons. These data strongly suggest that BACE1 can regu-
late neuronal function, possibly by cleaving Navb2i n
physiological conditions. In order to better understand
the role of BACE1 in Nav metabolism, we have identi-
fied the BACE1 cleavage site in human Navb2i nt h e
present study.
Materials and methods
Plasmids, transfection, and reagents
Expression constructs encoding full-length human
Navb2 (GenBank: NM_004588) containing a C-terminal
V5-His tag and full-length human BACE1 (GenBank:
AF190725) containing a C-terminal myc tag have been
described previously [11]. Navb2 (147LM/VI) and
Navb2 (147LM/AA) were constructed using Quick-
Change Site-directed Mutagenesis kit (Stratagene) with
the following primers: Navb2 (147LM/VI): 5’-GGCAA-
GATCCATCTGCAGGTCGTCATTGAAGAGCCCC
CTGAGCGG-3’ 5’-CCGCTCAGGGGGCTCTTCAAT-
GACGACCTGCAGATGGATCTTGCC-3’;N a v b2( 1 4 7
LM/AA): 5’-GGCAAGATCCATCTGCAGGTCGCCG
CGGAAGAGCCCCCTGAGCGG-3’ and 5-’CCGCTC
AGGGGGCTCTTCCGCGGCGACCTGCAGATGGAT
CTTGCC-3’. Effectene (Qiagen) was routinely used for
transfecting cell lines. GL189 (Calbiochem) was used in
10 μM concentration.
In vitro cleavage assay of Navb2 substrate peptide
Navb2 substrate peptide (b2-peptide) with N-terminal
biotin was synthesized by CHI Scientific (M.W. 4049.7,
purity = 94.02% determined by HPLC). A biotinylated
tyrosine group was added to the N-terminus of the
b2-peptide. Reaction mixtures containing 20 mg of
b2-peptide, 0.1 M Na-Acetate (pH 4.0), and 2.5 mg
human BACE1 (R&D systems), were prepared and
incubated at 37°C for 16 h. Reactions were stopped by
heating to 95°C with LDS-SDS-PAGE sample loading
buffer (Invitrogen) for 5 min.
Reaction samples were then resolved on 12% BisTris
gels (Invitrogen), transferred to PDVF membrane for
Western blot analysis or fixed directly for silver staining.
Vector ABC kit (Vector Labs) was used to detect full-
length and N-terminal fragment of b2-peptide in
Western Blot while Silver SNAP II kit (Invitrogen) was
used to detect total protein in the gel.
Mass spectrometry
Reaction samples from the b2-peptide in vitro cleavage
a s s a yw e r ea n a l y z e db yM Su s i n gaQ S t a r RP u l s a rI
(Applied Biosystems) equipped with a nanospray source
(in collaboration with Proteomic core at Harvard Part-
ners Center for Genetics and Genomics). Analyst soft-
ware (Invitrogen) was used to determine the molecular
weights of all cleavage products in the reaction mixture.
Western blot analysis
Cell lysates were prepared by directly extracting cells in
a buffer containing 10 mM Tris-HCl (pH 6.8), 1 mM
EDTA, 150 mM NaCl, 0.25% Nonidet P-40, 1% Triton
X-100, and a protease inhibitor cocktail (Roche) fol-
lowed by a centrifugation at 16,000 g. 20-50 mg of pro-
tein were resolved on 12% BisTris gels (Invitrogen). The
blots were visualized by enhanced chemiluminescence
(ECL). Images were captured using BioMax film
(Kodak) or VersaDoc imaging system (Biorad) and
quantified with QuantityOne software (Biorad). The fol-
lowings are antibodies used in this study: anti-V5
(1:5000; Invitrogen), anti-myc (1:2000: Cell Signalling)
anti-GAPDH (1:2000; BD Biosciences), and antiflotillin-
1 (1:250; BD Biosciences).
In vitro generation of Navb2-CTFb
Membrane preparation and in vitro generation of
Navb2-CTFb were performed as described earlier [23].
In brief, cells were washed with PBS, scraped in 1 ml
PBS and centrifuged for min at 8000 rpm. Cell pellets
were resuspended in 700 μl buffer H (20 mM HEPES,
150 mM NaCl, 10% glycerol, 5 mM EDTA, pH 7.4) and
the solution drawn 20 times through a 3 ml syringe
with 20 gauge needle. Unbroken cells were removed by
centrifugation at 4000 rpm for 5 min. In order to obtain
P2 fractions, the supernatant was centrifuged at 55000
rpm for 1 h and 4°C. Membrane fractions were washed
once in 300 μl incubation buffer (0.1 M Na Acetate pH
4.0, 10 μg/ml Leupeptin, 1 μg/ml Aprotinin, 1 mM PNT
and 5 mM EDTA) and resuspended in 100 μl incubation
buffer in absence or presence of GL189. After incuba-
tion for 3 h at either 0°C or 37°C, the samples were
loaded on 12% BisTris and investigated by Western blot
analysis.
Lipid Raft Fractionation
Cells were grown to 80-90% confluency in three
150-mm dishes, washed twice in phosphate buffered sal-
ine and scraped into 1.2 ml extraction buffer containing
0.5% Lubrol WX (Lubrol 17A17; Serva), protease inhibi-
tor cocktail (Roche) and 1 mM phenylmethylsulfonyl
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Page 2 of 9fluoride (PMSF). Cells were then homogenized by five
passages through a 25-gauge needle. Cell lysates were
adjusted to 45% final concentration of sucrose (final
volume, 4 ml) and loaded to the bottom of a 12-ml
SW41 ultracentrifuge tube. A discontinuous sucrose gra-
dient was established by sequentially layering 35%
sucrose (4 ml) and 5% sucrose (4 ml) on top of the sam-
ple. Tubes were subjected to ultracentrifugation at
39,000 rpm for 18 h in Beckman SW41 rotor at 4°C.
Twelve 1 ml fractions were collected from the top of
the gradient and equal volume of each fraction was ana-
lyzed by Western blotting. V5 antibody was used to
detect Navb2 and flotillin-1 antibody was used as a lipid
raft marker.
Immunocytochemistry
Cells were grown on coverslips to 20-40% confluency
and fixed with 4% paraformaldehyde for 20 min at room
temperature. Cells were then rinsed three times with
PBS and blocked for 1 h in PBS containing 1% BSA
(Sigma-Aldrich) 0.1% Triton X-100 (FisherBiotech), 0.1%
Gelatin (Sigma-Aldrich) and 0.05% Tween 20 (MP Bio-
medicals). Cells were incubated with anti V5 antibody
for 1 h, washed three times with PBS and incubated for
30 min with rabbit anti-mouse Alexa Fluor 488 antibody
(1:200: Serotec) at room temperature. After washing
three times with PBS containing 0.1% Triton X-100 and
0.05% Tween-20 for 3 min the coverslips were mounted
onto glass slides using Prolong Gold antifade reagent
with DAPI (Invitrogen) and analyzed with a Olympus
florescence microscope equipped with a confocal disk
scanning unit.
Results
Identification of BACE1 cleavage sites in human Navb2
To identify BACE1 cleavage sites in human Navb2, we
synthesized a substrate peptide (b2-peptide) correspond-
ing to a 32 amino acid sequence at the juxtamembrane
region of human Navb2 (Figure 1D). A biotinylated tyr-
osine group was added to the N-terminus of the b2-pep-
tide to detect N-terminal fragments. Reaction mixtures
containing the b2peptide and purified recombinant
human BACE1 were incubated at 37°C for 16 h. The
incubation of the b2-peptide with BACE1 specifically
increased cleavage products ~2 kDa, detected by both
silver staining and anti-biotin-HRP conjugate (Figure 1A
and 1B, lane #2). The generation of the 2 kDa cleavage
products was dramatically inhibited by the BACE1 inhi-
bitor GL-189 (Figure 1A and 1B, lane #3). The reaction
samples were then analyzed by mass spectrometry (MS)
to characterize all cleavage products (Figure 1C). Thus
we were able to identify a major (147-148 L↓M, where ↓
indicates the cleavage site) and a minor (144-145 L↓Q)
BACE1 cleavage site in the extracellular domain of
human Navb2 (Figure 1D). Interestingly, we found that
the major cleavage site of human Navb2 is slightly dif-
ferent from the one previously reported for mouse
Navb2 (Figure five, [12]). This difference might be due
to two amino acid changes, 143(H/Y) and 148(M/L)
close to the known BACE1 cleavage sites in human and
mouse Navb2.
Mutations of the BACE1 cleavage site decrease BACE1-
mediated processing of human Navb2 in purified CHO
cells membrane
To specifically measure BACE1-mediated cleavage of
Navb2, we used a cell-free BACE1-cleavage assay [21].
We introduced two separate double mutations,
147LM/VI and 147LM/AA at the S1 and S1’ positions
of the major BACE1 cleavage site (Figure 2A). Wild-
type and mutated human Navb2 were expressed in
CHO cells and crude membrane fractions prepared
from those cells were incubated for 3 h at pH 4.5 with
or without the BACE1 inhibitor GL-189. As expected,
wildtype Navb2 (WT) was cleaved at 37°C to generate
b2-CTFb, which is completely blocked by treatment
with GL-189 (Figure 2B, left panel). However, the
cleavage of Navb2 (147LM/VI) and Navb2 (147LM/
AA) is dramatically decreased (Figure 2B, middle and
right panel). These data strongly indicate that 147-148
L↓M is the major BACE1 cleavage site in human
Navb2.
Mutations of the BACE1 cleavage site do not affect
subcellular localization of human Navb2
To exclude the possibility that the mutations introduced
into Navb2 caused its retention in early compartments,
we studied the subcellular localization of the mutated
versus wildtype Navb2. We established enriched cultures
of CHO cells transfected with wildtype and mutated
Navb2 and investigated localization of Navb2b yf l o r e s -
cence confocal microscopy. We could not detect any
significant difference in the subcellular localization of
mutated Navb2 as compared to wildtype Navb2
(Figure 3A). These data were also confirmed in B104
cells (data not shown).
Next, we tested whether the distribution of Navb2
into cholesterol-rich domains (lipid rafts) is altered by
the 147LM/AA mutation. As previously reported, Navb2
was detected in lipid raft enriched fractions, confirmed
by flotillin-1 staining (Figure 3B, fractions 2 to 4, [12]).
We could not detect any significant changes in the
levels of Navb2 (147LM/AA) in lipid-raft fractions.
Together, these results suggest that localization of
Navb2 was not affected by mutations of the BACE1
cleavage site.
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+BACE1 
128 (226.0713)YLMNPPDRHRGHGKLHL  3  2267.138  3880000 
128 (226.0713)YLMNPPDRHRGHGKLHLQVL  2  2607.349  1980000 
128 (226.0713)YLMNPPDRHRGHGKLHLQVL  3  2607.349  45400000 
128 (226.0713)YLMNPPDRHRGHGKLHLQVL  4  2607.349  10800000 
128 (226.0713)YLMNPPDRHRGHGKLHLQVLMEEPPERDSTVAV  3  4048.005  13700000  22300000 
128 (226.0713)YLMNPPDRHRGHGKLHLQVLMEEPPERDSTVAV  4  4048.005  84200000  104000000 
145 QVLMEEPPERDSTVAV  2  1799.885  1320000 
148 MEEPPERDSTVAV  2  1459.674  24700000 
B  A 
kDa 
45 → 
30 → 
20 → 
14 → 
3.5 → 
2.5 → 
Figure 1 Identification of BACE1 cleavage sites in human Navb2 by MS analysis. Reaction mixtures from an in vitro BACE1 cleavage assay
were resolved on a 12% BisTris gel and full-length peptide and cleavage products were detected by silver staining. Only the incubation of the
b2-peptide with BACE1 generates a ~2 kDa cleavage product. GL-189, a BACE1 inhibitor, significantly decreased the amount of cleavage product
(lane 3). B) Western blot analysis of an in vitro BACE1 cleavage assay samples using anti-biotin-HRP conjugate. C) Table containing the major
cleavage products and their predicted sequences determined by Mass spectrometry from control and the BACE1 reaction sample. D) Sequence
of the b2-peptide synthesized for the in vitro cleavage assay. A biotinylated tyrosine amino acid is added to the N-terminus of the peptide for
detection by anti-biotin-HRP conjugate. One major (big arrow) and one minor (small arrow) BACE1 cleavage site were detected by MS analysis.
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processing in cell based models
To further investigate the identified major BACE1 clea-
vage site (147-148 L↓M), we tested whether 147LM/VI
and 147LM/AA mutations would also reduce Navb2
cleavage in cells. Wildtype and mutated Navb2w e r e
transfected into B104 rat neuroblastoma cells stably
overexpressing BACE1. a-secretase-mediated processing
of Navb2 would not be affected by mutations in the
BACE1 cleavage site. Therefore, we did not expect com-
plete inhibition of Navb2 processing in cells expressing
the mutated form of the protein. Indeed, we found that
Navb2-CTF production was decreased by ~50% in cells
expressing Navb2 (147LM/VI) and reduced by ~75% in
cells expressing Navb2 (147LM/AA) as compared to
wildtype Navb2 expressing cells (Figure 4A and 4B). In
addition, we transfected wildtype Navb2a n dN a v b2
(147LM/VI) together with BACE1 into CHO cells. Simi-
lar to B104 cells, mutation of the identified BACE
cleavage site strongly reduced Navb2-CTF production
(data not shown). These data confirm that 147-148 L ↓
M is the major BACE1 cleavage site in human Navb2.
Discussion
Using a similar synthetic peptide substrate and MALDI-
MS, Wong et al. previously reported that 144-145 L↓Q
is the major BACE1 cleavage site of mouse Navb2 [12].
It is interesting that the major cleavage site of human
Navb2i ss l i g h t l yd i f f e r e n tf r o mt h a to fm o u s eN a v b2
( F i g u r e1 Da n d5 ) .T h em o u s eB A C E 1c l e a v a g es i t eo f
Navb2 is similar to the minor (144-145 L↓Q) BACE1
cleavage site in the human Navb2i d e n t i f i e di no u r
study. This site difference may be due to amino acid dif-
ferences between human and mouse Navb2. As shown
in Figure 5 there are two amino acid changes between
human and mouse, in proximity to the BACE1 cleavage
sites Navb2 (143(H/Y) and 148(M/L)). Particularly, the
148(M/L) site is located in the S1’ position of the
BACE1 cleavage site of human Navb2. According to
Turner et al., a methionine at S1’ position in human
Navb2i sh i g h l yp r e f e r a b l ef o rB A C E 1c l e a v a g ea s
compared to a leucine [24]. Further studies will be required
to confirm this cleavage site in brains and to explain
whether changes in the BACE1 cleavage site between spe-
cies would lead to a differential regulation of sodium chan-
nel metabolism in human as compared to mouse.
A recent study identified 68 BACE1 substrates, under-
scoring the role of BACE1 in various cellular processes
[8]. Similarly to Navb2 ,t h em a j o r i t yo ft h o s es u b s t r a t e s
are, type 1 transmembrane proteins with extracellular
N-terminal and intracellular C-terminal ends. However,
in addition to Navb2 only a few BACE1 substrates have
been confirmed under physiological conditions. These
include APP, Neuregulin 1/3 (NRG-1/3), alpha 2,6-sia-
lyltransferase (ST6GAL1), and P-selectin glycoprotein
ligand-1 (PSGL1) [6, 912]. As shown in Figure 5 the
BACE1 cleavage sites in these substrates show highly
similar sequences. For example, the S1 cleavage position
has been suggested as the most important site for deter-
mining BACE1-mediated processing based on an in
vitro cleavage assay using synthetic substrate peptides
[24]. The majority of substrates harbor leucine, phenyla-
lanine, or methionine at the S1 cleavage site. Interest-
ingly, human Navb2 harbors both leucine and
methionine at the S1 and S1’ position, which are the
most preferable residues at those positions according to
in vitro studies [24]. These studies also suggest, that
subsites proximal to the scissile bond (S1 and S’1) are
more stringent than distal residues which is reflected by
the drastic decrease in CTF production in Navb2h a r -
boring mutations 147LM/AA or 147LM/VI.
In our previous studies, we have found that elevated
BACE1-mediated cleavage of human Navb2i n c r e a s e d
Navβ2 (147ML/VI)  Navβ2 (147ML/AA)  Navβ2 (WT) 
T in °C  0  37  37  0  37  37  0  37  37 
GL189 -  -  +  -  -  +  -  -  + 
kDa 
52→  
38→  
31→  
17→  
12→  
TM 
Ig-like domain 
β-cleavage  γ-cleavage 
N  C 
---PDRHRGHGKIHLQVLMEEPPERDSTVAVIVGASVG---
---PDRHRGHGKIHLQVVIEEPPERDSTVAVIVGASVG--- 
---PDRHRGHGKIHLQVAAEEPPERDSTVAVIVGASVG---
Navβ2 (WT) 
Navβ2 (147ML/VI) 
Navβ2 (147ML/AA) 
B 
A 
Figure 2 Characterization of the major BACE1 cleavage site in
an in vitro assay. A) Schematic representation of the Navb2
(147ML/VI) and Navb2 (147ML/AA) mutations introduced into the
identified major BACE1 cleavage site. B) Cell-free generation of
Navb2-CTF in membranes from CHO cells expressing Navb2
wildtype, Navb2 (147ML/VI) or Navb2 (147ML/AA). Treatment with
the BACE inhibitor GL189 inhibited cleavage of wildtype Navb2.
Navb2-CTF generation is nearly abolished in Navb2 (147ML/VI) and
Navb2 (147ML/AA).
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Page 5 of 9Navβ2 (WT)  
Navβ2 (147ML/VI)  
Navβ2 (147ML/AA)  
Nuclei 
Nuclei 
Nuclei 
Merged 
Merged 
Merged 
I II  III 
IV V  VI 
VII VIII  IX 
Fraction #      1     2     3     4     5      6     7     8     9    10  11 
Navβ2 
Flotillin-1 
Navβ2  (WT)  Navβ2  (147LM/AA) 
B 
A 
1     2     3      4     5      6     7     8     9    10  11 
Figure 3 Similar subcellular localizations of Navb2 (147LM/VI) and Navb2 (147LM/AA) as compared to wildtype Navb2. A) Confocal
images of enriched cultures expressing Navb2 wildtype, Navb2 (147ML/VI) or Navb2 (147ML/AA) immunostained with a C-terminal V5 antibody.
B) Western blot analysis of cells expressing either wildtype Navb2 or Navb2 (147LM/AA) subjected to sucrose gradient fractionation. Flotillin-1
staining marks lipid raft fractions. The Navb2 (147ML/VI) and Navb2 (147ML/AA) mutations in the BACE1 cleavage site did not visibly affect
subcellular or lipid raft localization of Navb2.
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Page 6 of 9mRNA and protein levels of Nav1.1 a subunit by
increasing the release of the b2 intracellular domain
(Navb2-ICD) [21]. Therefore, it will be interesting to see
whether the blockage of BACE1 cleavage in Navb2
147LM/IV and Navb2 147 LM/AA would also decrease
Nav1.1 levels by decreasing Navb2-CTF levels and possi-
bly Navb2-ICD levels. However, these studies are diffi-
cult because a-secretase cleavage of Navb2i sn o t
affected by the 147 LM/VI and 147 LM/AA mutations.
On the contrary, we have observed elevated a-secretase
cleavage in CHO cells transiently expressing Navb2 (147
(LM/AA) (data not shown). The a-secretase cleavage
site is distinct from and closer to the membrane than
the BACE1 cleavage site, unlikely to be directly affected
by the BACE1 cleavage site mutations [21,25]. It is more
likely that the elevated a-secretase cleavage observed
only in CHO cells is due to a compensatory asecretase-
mediated cleavage since BACE1 and a-secretase seem to
compete for juxtamembrane cleavages as shown in APP
processing. Additional mutations completely blocking a-
secretase-mediated cleavages will be required to fully
address the role of BACE1 in sodium channel metabo-
lism in normal conditions.
BACE1 levels and activities are significantly elevated in
AD brains, possibly contributing to the disease progres-
sion [26-28]. BACE1 levels are also increased in some
injury conditions including brain trauma [29] and ische-
m i a[ 3 0 - 3 2 ] ,s u g g e s t i n gap o s s i b l er o l eo fB A C E 1a sa
stress-response protein [2]. The fact that BACE1 regu-
lates Nav channel metabolism via Navb2 suggests the
interesting possibility that BACE1 might modulate
sodium channel metabolism not only in AD but also in
other disease conditions in which BACE1 levels are
increased. It will be interesting to test whether the
BACE1cleavage mutation in Navb2 reported here would
also alter sodium channel metabolism in various stress
conditions including oxidative stress and mitochondrial
dysfunctions, which are known to increase BACE1
levels.
A 
Navβ2  
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Navβ2  
(WT) 
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38→
38→
17→
76→
38→
← β2-FL 
← β2-FL 
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Figure 4 Mutations in the BACE1 cleavage site strongly
decrease processing of Navb2 in B104 cells overexpressing
BACE1. A) B104 cells stably overexpressing BACE1 were transfected
with Navb2 wild-type, Navb2 (147ML/VI) or Navb2 (147ML/AA) and
then subjected to Western blot analysis. B) Quantification of Navb2-
CTF to Navb2-FL ratios from A. Navb2-CTF levels were decreased by
mutations in the BACE1 cleavage site (FL, full length; CTF, C-terminal
fragment).
S4 S3  S2 S1  S1' S2'  S3' S4' 
Navβ2 K I H  L Q  V  L  M E E  P P E  R 
Navβ2 (mouse) G H G  K  I  Y  L  Q  V  L  L  E E P 
APP E I S  E V  K M  D A E  F R H  D 
APP (Swedish) E I S  E V  N  L  D A E  F R H  D 
NRG1 K H L  G  I E  F  M  E  A  E  E L Y 
ST6GAL1 D Y E  A  L T  L  Q  A  K  E  F Q  M 
PSGL1 K Q A  A  S N  I  S  V  N  Y  P V  G 
Amino acid preferences: E>Q>D  I>V>L  D>N>M L>F>M>Y M>E>Q>A V>I>A L>M>A D>E>W 
Figure 5 Cleavage sequence comparison among BACE1 substrates. A black arrow indicates the currently characterized BACE1 cleavage sites
of BACE1 substrates. Amino acid preferences around the BACE1 cleavage sites were determined by Turner R.T. et al. [24]. Interestingly, human
Navb2 harbors the preferable residues at S1 and S1’, the most important positions for BACE1 recognition and cleavage.
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Page 7 of 9Conclusion
We identified a major (147-148 L↓M) and a minor (144-
145 L↓Q) BASE1 cleavage site in human Navb2 by using
a synthetic b2-peptide and MS. We also found that
mutations of the major BACE1 cleavage site (147LM/VI
and 147 LM/AA) dramatically decreased BACE1-
mediated cleavage of human Navb2i na nin vitro assay
and a cell based model. Our data clearly demonstrate
that the BACE1 cleavage site (147-148 L↓M) is mainly
responsible for BACE1 cleavage of human Navb2.
Abbreviations used
APP: amyloid precursor protein; Ab: amyloid b peptide; Nav: voltage-gated
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